Skip to content

Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Chronic Heart Failure: Cardiovascular Effects

Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Chronic Heart Failure: Cardiovascular Effects

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04443426
Acronym
KETO-KINETICS1
Enrollment
8
Registered
2020-06-23
Start date
2019-04-25
Completion date
2022-11-01
Last updated
2022-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Ketosis, Ketonemia

Keywords

Metabolism

Brief summary

The ketone body 3-hydroxybutyrate (3-OHB) is a naturally occurring energy substrate, and is associated with increased life span and improved health. We have previously shown that intravenous 3-OHB treatment increases myocardial blood flow \> 70% in healthy humans and data from our group show that 3-OHB increases cardiac output by 40 % in patients with heart failure. In this study the investigators aim to investigate: 1. If this effect is reproducible with a commercially available oral ketone supplements 2. The safety of commercially available ketone supplements in heart failure patients

Detailed description

Heart Failure (HF) is a major public health issue because the disease affects 1-2% of the Western population and the lifetime risk of HF is 20%. HF is responsible for 1-2% of all healthcare expenditures. Despite major improvements in the management and care of patients with HF, the 1-year mortality in patients with HF is 13 % and \>50% of HF-patients is admitted during a 2.5 year period. Furthermore patients with HF have markedly decreased physical capacity and quality of life. Thus, there is a need for new treatment modalities in this group of patients. Ketone bodies are produced in the liver and are of vital importance in the human body for energy generation in the heart and brain during fasting, exercise and severe illness. Ketosis can be safely obtained using dietary supplements and can increase exercise capacity in athletes. The most important ketone bodies are 3-hydroxybutyrate (3-OHB) and acetoacetate. Recently, it was demonstrated that patients with severe HF have increased myocardial utilization of the ketone body 3-hydroxybutyrate. We have shown, using positron emission tomography, that ketone body infusion reduces myocardial glucose uptake and increases myocardial blood flow in healthy subjects. Data from another study conducted by our group show a 40% increase in cardiac output during infusion of 3-OHB. Presently there are no data on the clinical cardiovascular and metabolic effects of long-term oral ketone-supplementation in patients with chronic HF. In this study the investigators will whether ketosis obtained by oral ketone supplements affects hemodynamics and contractile function.

Interventions

DIETARY_SUPPLEMENTOral 3-hydroxybutyrate salts

Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.

DIETARY_SUPPLEMENTCarbohydrate Placebo

Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.

DIETARY_SUPPLEMENTKetone Monoester

Commercially available ketone monoester in a dosage isocaloric to 3-OHB salts.

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Chronic Heart Failure; * NYHA class II-III * Left Ventricular Ejection Fraction \<40%

Exclusion criteria

* Diabetes or HbA1c \> 48 mmol/mol * Significant cardiac valve disease, * Severe stable angina pectoris * Severe comorbidity as judged by investigator, * Inability to give informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Cardiac Output (L/min)5 hours - Area under the curveRight Heart Catherization

Secondary

MeasureTime frameDescription
Left Ventricle Ejection Fraction (%)5 Hours - Area under the curveEchocardiography
Left Ventricular filling pressure (mmHg)5 hours - Area under the curveRight Heart Catherization

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026